Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Must Have Stocks For Your Watchlist!
Company stocks are seen dropping to 2020 levels and it could be a considerable time for them to be greedy. (hooray to those who have spare cash to invest)
With multiple losses experienced by companies in recent quarter release, fears of a recession plague the market, the number of stocks considered undervalued breached levels seen at worst points of Covid-19 triggered recession
The U.S. market now trades at about a 15% discount, as overvalued stocks drop and stocks already trading at a bargain fall further into discount territory. As of July 19, the number stocks considered undervalued rose to 514, up from 289 at the end of the first quarter, an almost 78% increase.
A few companies to name are ,
1. Grupo Televisa (TV)
2. Infineon Technologies (IFNNY)
3. Regencell Bioscience (RGC)
4. Ingersoll Rand (IR)
5. Goldman Sachs (GS)
## **Grupo Televisa**
“We remain bullish on Televisa's long-term prospects. Historically a powerhouse in Spanish-language media because of its programming prowess and ownership of the leading broadcast networks in Mexico, the firm merged its media business into Univision. Televisa is now focused on telecom. The firm transformed itself into a leading telecom firm in Mexico through a series of acquisitions and is now one of the country’s fastest-growing broadband providers.”
## **Infineon Technologies**
“Infineon is a leading broad-based European chipmaker, with substantial exposure to secular growth drivers in the industrial and automotive chip sectors. Infineon should emerge as a leading supplier for electric vehicles and active safety systems used in cars, with increasing exposure to car "infotainment" systems. However, like most chipmakers, Infineon's business remains highly cyclical as demand ebbs and flows in line with the health of its various end markets.”
## Regencell Bioscience Holding
“CEO has been pledging been a strong supporter and putting his personnel funds in depending the company from short traders and hedge funds. The CEO has also pledged to not draw salary and bonus of more than USD $1 until the Company reaches USD $1 billion market capitalization and will not award share options for himself; Further more, all directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.”
## **Ingersoll Rand IR**
“On Feb. 29, 2020, Gardner Denver acquired former Ingersoll-Rand’s industrial business in a transformative Reverse Morris Trust transaction. The combined entity took on the Ingersoll-Rand name and stock ticker.
“Following the merger, new Ingersoll-Rand is a leading mission-critical flow creation and industrial technology company. The combined entity operates under two reportable segments: 1) industrial technologies and services; and 2) precision and science technologies, including Gardner Denver's medical business. The combined business will benefit from a more comprehensive portfolio of products and services. Ingersoll-Rand’s large installed base of equipment generates a relatively stable stream of aftermarket and service revenue, which accounts for roughly 36% of combined pro forma sales.”
## **Goldman Sachs**
“Goldman Sachs has made progress on the strategic plan that it laid out at the beginning of 2020 and set even more ambitious goals in 2022. The company is now targeting a medium-term return on tangible equity (ROTE) of 15% to 17% compared with a previous goal of over 14%. In addition to the ROTE target, management also set an expense ratio goal of about 60% and growth targets for its asset management and consumer banking businesses. While we’re not sure the company will hit all of those goals over the next three years, we forecast the company exceeding a 15% ROTE in the long run after its consumer business has reached a more profitable scale. Goldman Sachs’ trading business also remains a large swing factor, as it requires more capital and tends to have lower operating margins than the other business segments.”
[https://www.morningstar.com/articles/1103336/8-newly-undervalued-5-star-stocks]
Missed Company Earnings, Market goes down. Time to Diversity to this stock.
In recent weeks since market has touched levels that, said that are the low point of the current bear market, there’s been a change in leadership among best performing sectors.com
For most of the first half of 2022, the only sector posting gains was energy, with utilities living up to their defensive reputation and posting the smallest losses among the 10 remaining sectors.
But since June 16, technology and consumer cyclical stocks are the leading sectors after being hit harder than the rest of the market in the first half of the year. Stocks leading the bounce include Amazon (AMZN), Tesla (TSLA), Home Depot (HD), and McDonald’s (MCD).
But watchful eyes are looking out on whether it is just a relief rally or a more durable trend.
Good investors should not time the market, but to adapt and rotate based on the market sentiment and trend. Defensive stocks are a recommendation for all cautious investors ie. Healthcare, Utility, F&B and REITS.
A small cap healthcare industry which has not yet reach mainstream media is Regencell Bioscience Holding (RGC).
RGC is an early bioscience healthcare company which focuses on R&D and commercialization treatment of ASD, ADHD and COV19 using Traditional Chinese Medicine (”TCM”) method.
Unlike some early-stage companies, where it can be difficult to parse the many ways in which founders and executives may benefit whether or not the company succeeds, RGC has taken a more transparent approach that is well-aligned with shareholders’ long-term interests.
Some highlights about the company executives and founders, showing long term conviction in the company:
- CEO to draw only $1 annual salary and no bonus until the company reaches a $1 billion market capitalization
- CEO to continue company share buyback to demonstrate commitment to the Company and position against short and distort sellers.
- All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
This brings to a healthcare stock which had been recently IPO last year July 22’ which had seen a a good run of 300% capital gains after listing. Shares have taken a heavy hit from short sellers and hedge funds whom had strategically targeting the company stock. However RGC had recovered to the $30s, encouraged by study results for Regencell’s RGC-COV19 Traditional Chinese Medicine (TCM) formula for treating COVID-19 symptoms, frequent shareholder communication, and support for the shares in the market.
[https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx](https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx)
Undervalue Biotech Stocks
Although recession may be on everyone's mind, these undervalued biotech stocks to buy feature extraordinary relevance at a great price.
With fears of a global recession rising, it’s natural that investors have turned their back on growth-intensive names. However, this backdrop has also yielded compelling undervalued biotech stocks to buy. While very few sectors have been spared the damage stemming from soaring inflation, geopolitical instability and supply chain disruptions, the biological sciences arena offers long-term relevance.
Mainly, it doesn’t matter whether a recession is about to capsize our economy or not. Since humans remain vulnerable to various diseases and medical conditions, it’s imperative that researchers continue to move forward. Therefore, undervalued biotech stocks to buy command significant interest because at some point, they have the potential to rise substantially higher.
To be fair, the underlying sector is volatile. And many times, a company sheds basis points in the equities market for a reason — often not a good one. Still, if you have some spare funds for speculation, these undervalued stocks to buy could offer significant bang for your buck.
1. BioMarin Pharmaceutical (BMRN): With its stable balance sheet, BioMarin Pharmaceutical is well-equipped to focus on therapies for rare diseases.
2. Ionis Pharmaceuticals (IONS): One of the undervalued biotech stocks to buy with a very wide footprint, Ionis Pharmaceuticals provides a compelling case for investors.
3. Exelixis (EXEL): An advanced therapeutics firm for cancer treatment, Exelixis also enjoys a robust balance sheet, providing confidence to prospective shareholders.
4. Intuitive Surgical (ISRG): Specializing in minimally invasive surgery, Intuitive Surgical makes for one of the most intriguing undervalued biotech stocks to buy.
5. Regencell Bioscience (RGC): Focusing on treatment of ADHD, ASD and COV19 via Traditional Chinese Medicine (”TCM”) method. Stock under radar of short sellers and traders. Might be a great pick for short squeeze players.
6. Affimed (AFMD): Leveraging the body’s immune system to target and kill tumor cells, Affimed could be a great deal to pick up for speculators.
7. Vir Biotechnology (VIR): Featuring cutting-edge technologies to combat infectious diseases, the pandemic has brought much relevance to Vir Biotechnology.
8. CRISPR Therapeutics (CRSP): An exciting though controversial gene-editing firm, CRISPR Therapeutics may be one of the undervalued biotech stocks to buy for the bold contrarian.
(https://finance.yahoo.com/news/stock-market-news-live-updates-july-27-2022-113235652.html)
Shorted this company in the past. Made good sum.
Regencell Bioscience Limited’s (NASDAQ:RGC) is a bioscience *healthcare* company that focuses on heavily on R&D and commercialisation of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.
The company has seen a good rise of over 300% since taking the company IPO in July 2021, and have seen on a roller coaster ride between euphoria and depression in the recent months.
Analyst has covered that RGC has a undiscovered short squeeze potential. Similarities are found between RGC and GameStop Corp. $GME, where both short volume ratio are over 40% in the past year, with periods where RGC is a more heavily shorted counter than GME (~90% shorted).
As of May 16th 2022, RGC’s Founder & CEO holds 81% of total issued and outstanding ordinary shares (10,539,159). RGC’s total cumulative short volume as reported by 3rd party data analytics is over 19 million shares. Moreover, the total reported short volume to outstanding shares (excluding CEO and chairman ownership ratio) is over 7 times, which is almost 2x of GME.
(https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/)
Top Performing IPO for 2021 & 2022; $RGC
The year 2021 has seen a huge number of 1,035 companies taking IPO in the US market; where the huge piece of the listings (35%) were in the biotech & healthcare sector. (A possible move by companies to ride on the Covid / Healthcare wave; just thinking out loud).
The company which had the largest gains since IPO does not turn heads when mentioned nor is it a name you seen in ads on television or YouTube. But this company was in the sight of many hedge funds and traders for a while period.
Regencell Bioscience (NASDAQ:[RGC](https://www.benzinga.com/stock/RGC#NASDAQ)). RGC is the top performing stock of all 2021 IPOs according to stockanalysis.com/ipos/2021/. As of August 1, 2022, RGC is still ranked #1 with a 237% return above its IPO price of $9.50.
[A June 2022 article]( https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i) mentioned that RGC’s total cumulative short volume is over 19 million shares. While the stock has suffered from short sellers’ attacks since its listing, RGC has performed well. RGC has approximately 2.6 million tradable ordinary shares in the market and has maintained a low float as the founder and CEO has repeatedly purchased RGC ordinary shares from the open market.
For year 2022, the company which shot to the moon since IPO is AMTD Digital (NYSE:[HKD]) (https://www.benzinga.com/stock/HKD#NYSE)), a company founded by Mr. Li Ka-Shing’s Cheung Kong Group and Hutchison Whampoa in 2003. HKD’s IPO price was $7.80 and has gained over a staggering 9,000% since, closing at $742.00 on August 1, 2022.
Although RGC is the #1 performer of 2021 IPOs, this pales in comparison with the current performance of HKD. Astute traders who have an eye for forensic analysis in companies with low float and outsized short interest are indeed very happy.
Comparison between the 2 companies can be found in the article link shard at the end of page.
(https://www.benzinga.com/amp/content/28316977)
Possible Short squeeze Play on Healthcare Counter #RGC
Regencell Bioscience Limited’s (NASDAQ:RGC) stock that has seen a good rise of over 300% since taking the company IPO in July 2021. The company is a bioscience **healthcare** company that focuses on heavily on R&D and commercialization of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.
Analyst has covered that RGC has a undiscovered short squeeze potential. Similarities are found between RGC and GameStop Corp. $GME, where both short volume ratio are over 40% in the past year, with periods where RGC is a more heavily shorted counter than GME (~90% shorted).
As of May 16th 2022, RGC’s Founder & CEO holds 81% of total issued and outstanding ordinary shares (10,539,159). RGC’s total cumulative short volume as reported by 3rd party data analytics is over 19 million shares. Moreover, the total reported short volume to outstanding shares (excluding CEO and chairman ownership ratio) is over 7 times, which is almost 2x of GME.
[https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/]
Latest short volumes taken from https://fintel.io/ss/us/rgc#](https://fintel.io/ss/us/rgc#
Regencell (RGC) was top performing IPO Stock in 2021 with 237% return above its IPO price of $9.50
The year 2021 was the busiest year for deals since 2000, with over a thousand (1035 nos) listed companies in the United States. Biotech and Healthcare sectors took an overwhelming portion of 36% of the total IPO listed.
While it is not the strategy for most investors to target IPO shares, it is a surprise that the top performing IPO counter is a company with does not turn heads when mentioned. (ie. not a household name or famous company).
Regencell Bioscience (NASDAQ:RGC). RGC is the top performing stock of all 2021 IPOs according to [stockanalysis.com/ipos/2021/](http://stockanalysis.com/ipos/2021/). As of August 1, 2022, RGC is still ranked #1 with a 237% return above its IPO price of $9.50.
An article published in June 2022 has covered that RGC’s total cumulative short volume is over 19 million shares. While the stock has suffered from short sellers’ attacks since its listing, RGC has performed well. RGC has approximately 2.6 million tradable ordinary shares in the market and has maintained a low float as the founder and CEO has repeatedly purchased RGC ordinary shares from the open market.
Some key foundation points from the company,
As mentioned above, RGC is closely held by the CEO who owns over 81% of the company. He has used $5.9 million of his personal funds to purchase RGC shares from the open market since its IPO.
His consistent share purchases convey his confidence, commitment and conviction in the company and is putting his money where his mouth is. There are few companies that have the CEO owning this much of the business. The company’s entire management team has also extended the lock-up period of their share options, which shows they are collectively committed to their goal and mission, which is to save and improve lives.
(https://www.benzinga.com/amp/content/28316977)
These Stocks have Potential to gain 40%
The first 6 months in the market has been a nose dive towards bearish territory, but it’s seem to taken a U-turn in July. Despite Friday’s pullback, the monthly gains are solid, almost 5% on the S&P 500 and 7.5% on the NASDAQ, marking a turnaround from the long drop we saw earlier.
The million dollar question in many investor’s mind is, is this turnaround real or just a temporary relief before the dive resumes. That remains to be seen, but either way, even if the market reverts to its bearish trend, there will be opportunities for investors - finding them will be the key to success.
>>Allogene Therapeutics, Inc. (ALLO)<<
The first stock, Allogene Therapeutics, is a biopharmaceutical company pursuing research in cancer immunotherapies, using allogenic chimeric antigen receptor T-cells, or AlloCAR T, to develop new agents for disease treatment. These are purpose-designed precision medicines that work with the patient’s own immune system to attack cancers. The company is at the clinical stage, with several drug candidates undergoing human clinical trials.
In recent news on the clinical front, Allogene’s most advanced candidate, ALLO-501A, received regenerative medicine advanced therapy (RMAT) designation from the FDA, giving the program an expedited status. ALLO-501A’s new designation followed on a positive data release from the ALPHA2 trial, which is testing the drug on patients with relapsed or refractory Large B cell Lymphoma (LBCL). The data showed that AlloCAR T therapies are safe and effective, and produce durable patient responses. The company plans to initiate a Phase 2 pivotal trial this year.
>>>Prometheus Biosciences (RXDX)<<<
The next Goldman pick we’re looking at is another biopharma in the precision medicine niche. Prometheus is working on new treatments for immune-related gastrointestinal conditions, with a focus on inflammatory bowel diseases (IBD). Most of Prometheus’ program is in early, preclinical stages, but the company does have one drug candidate, PRA023, currently undergoing three human clinical trials to treat Ulcerative Colitis, Crohn’s Disease, and Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD). The company uses a biomarker-targeted therapeutic approach, based upon a patient’s biomarker profile. This patient-centric mode offers the promise of transformed patient outcomes.
Prometheus has recently reported several updates to its clinical trial programs of PRA023. First, the company has initiated a third Phase 2 study of the drug candidate, focusing on SSc-ILD. The study was initiated in March of this year, and top line results are expected in 1H24.
>>>Regencell Bioscience (RGC)<<<
An under the radar counter which has a possibility of moonshot is Regencell Bioscience Holding. Regencell Bioscience Holdings Limited (Nasdaq: RGC) is an early-stage bioscience company that focuses on the R&D and commercialization of Traditional Chinese Medicine (”TCM”) for the treatment of neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder **(”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19.
From the latest findings, Regencell Bioscience’s (TCM) treatment formula has so far treated 12 / 19 patients (suspected or confirmed COVID cases), and their health records showed improvements after an average treatment period of 5 days.
The company’s CEO and chairman noted “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."
The company’s current plan is to trade, manufacture, market and distrubte the TCM formulae for the treatment of COVID-19 to ASEAN countries, India, Japan, Australia and New Zealand.
Aside from the Company’s mission to threat people with ADHD and ASD, the company CEO, Mr Au is also involved in his own philanthropic project (within personal capacity) and aims to provided care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties. As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
[https://finance.yahoo.com/news/buy-2-stocks-jump-40-090447531.html]
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
Top Performing IPO Stock Of 2021: $RGC TOP PERFORMER
2021 was the busiest year for deals since 2000, with a record-breaking IPO rush of 1,035 listings in the US, with the biotech and healthcare sectors leading the way, accounting for 36% of all IPO activity.
While most investors are busy reviewing stocks in their current portfolio, it may come as a surprise which company came in first for stock return. Although it is currently not a household name, any savvy investor should definitely keep this stock on their radar: Regencell Bioscience (NASDAQ:RGC). RGC is the top performing stock of all 2021 IPOs according to stockanalysis.com/ipos/2021/. As of August 1, 2022, RGC is still ranked #1 with a 237% return above its IPO price of $9.50.
A June 2022 article mentioned that RGC’s total cumulative short volume is over 19 million shares. While the stock has suffered from short sellers’ attacks since its listing, RGC has performed well. RGC has approximately 2.6 million tradable ordinary shares in the market and has maintained a low float as the founder and CEO has repeatedly purchased RGC ordinary shares from the open market.
RGC’s Solid Foundation
As mentioned above, RGC is closely held by the CEO who owns over 81% of the company. He has used $5.9 million of his personal funds to purchase RGC shares from the open market since its IPO.
His consistent share purchases convey his confidence, commitment and conviction in the company and is putting his money where his mouth is. There are few companies that have the CEO owning this much of the business. The company’s entire management team has also extended the lock-up period of their share options, which shows they are collectively committed to their goal and mission, which is to save and improve lives.
For graphical charts, kindly refer to the site source: https://www.benzinga.com/amp/content/28316977
CEO Holding Majority Share, what does it entail?
Company CEO of Regencell Bioscience Holding (NASDAQ: RGC), Mr Yat-Gai Au has been buying back shares over the year. (over 68.34k shares with average price of $USD 26). The company stock price dropped in last month’s lowest of $USD 28.60 becoming its new support line.
Analyst data recorded that Mr Au’s recent purchase of shares was the biggest made as an insider individual.
That means that an insider was happy to buy shares at above the current price. It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares.
As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. Yat-Gai Au was the only individual insider to buy shares in the last twelve months.
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests.
Regencell Bioscience Holdings insiders own 81% of the company, currently worth about US$260m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
[https://finance.yahoo.com/news/founder-regencell-bioscience-holdings-limited-101443485.html](https://finance.yahoo.com/news/founder-regencell-bioscience-holdings-limited-101443485.html)
Early investors of Regencell Bioscience - Spoiler: Individual was also early supporter of Zoom
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialisation of Traditional Chinese Medicine (TCM) treatment specifically ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), and infectious diseases affecting people’s immune system such as COVID.
The stock price has seen >300% growth since IPO and had seen heavy sell off during period of mid June, however is seen bounced around 40% since the lows in June.
Of course one of the biggest and strongest supporter of the company share is no other than the company ) who believes in a better and brighter future for the company.
The founder and company CEO, (Mr Yat-Gai Au) in supporting of his commitment,confidence and his position towards the company, he has deployed over $5 million dollars of his own personel reservers in buying back company stock to reposition against possible short and distort sellers.
Another prominent early investor of RGC is Mr Samuel Chen, who is a very succesful early **Zoom Video Communications, Inc.** investor (Nasdaq: Zoom). Mr Samuel owned 8.8% of Zoom shares and was the second largest individual investor.
To date, Mr. Au has converted his shareholders’ loan of $3.25 million to Regencell’s ordinary shares upon listing and has pledged not to draw a salary and bonus of more than $1 until Regencell reaches a $1 billion market capitalization and reserved share options for all employees except himself.
In addition, in demonstrating the management’s commitment towards the company, all all directors and employees who were previously granted stock options upon Regencell’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
[https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i](https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i)
Share Price movement in Healthcare Company $RGC
The Fed is raising interest rates aggressively in an attempt to tame raging inflation and this has been hurting many stock investors who’s seeing bleeding portfolios on their phone or desktops.
Companies are predicted to slash forecasted earnings in the coming earnings quarter due to the high inflation rates and possible slowdown in earnings.
In an interview with MoneyWise earlier this year, Investor Rick Rule said, “I do not believe that the broad equities market will handle multiple rate hikes.”
Rule doesn’t suggest bailing on stocks completely.
This brings to a healthcare stock which had been recently IPO last year July 22’ which had seen a a good run of 300% capital gains after listing. Shares have taken a heavy hit from short sellers and hedge funds whom had strategically targeting the company stock. However RGC had recovered to the $30s, encouraged by study results for Regencell’s RGC-COV19 Traditional Chinese Medicine (TCM) formula for treating COVID-19 symptoms, frequent shareholder communication, and support for the shares in the market.
The formulae candidates aim to address the fundamental causes of disorders while alleviating symptoms and improving overall health at the same time. Taking a holistic approach, RGC’s TCM uses natural ingredients to treat different elements in the body and every bodily function is taken into consideration when preparing the TCM formulae for patients.
Unlike some early-stage companies, where it can be difficult to parse the many ways in which founders and executives may benefit whether or not the company succeeds, RGC has taken a more transparent approach that is well-aligned with shareholders’ long-term interests.
Some highlights about the company executives and founders, showing long term conviction in the company:
- CEO to draw only $1 annual salary and no bonus until the company reaches a $1 billion market capitalization
- CEO to continue company share buyback to demonstrate commitment to the Company and position against short and distort sellers.
- All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
In the next few months, RGC expects to report data from its second clinical study of its standardized TCM formula for the treatment of ASD and ADHD.
We will then findout if the company has been making positve progress on the company when the report becomes available.
[https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx](https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx)
Want to Ride Out Market Volatility? Diversity into this small cap with high upside!
In recent weeks since market has touched levels that are the low point of the current bear market, there’s been a change in leadership among best performing sectors.
For most of the first half of 2022, the only sector posting gains was energy, with utilities living up to their defensive reputation and posting the smallest losses among the 10 remaining sectors.
But since June 16, technology and consumer cyclical stocks are the leading sectors after being hit harder than the rest of the market in the first half of the year. Stocks leading the bounce include Amazon (AMZN), Tesla (TSLA), Home Depot (HD), and McDonald’s (MCD).
But watchful eyes are looking out on whether it is just a relief rally or a more durable trend.
Good investors should not time the market, but to adapt and rotate based on the market sentiment and trend. Defensive stocks are a recommendation for all cautious investors ie. Healthcare, Utility, F&B and REITS.
A small cap healthcare industry which has not yet reach mainstream media is Regencell Bioscience Holding (RGC).
RGC is an early bioscience healthcare company which focuses on R&D and commercialsation treatment of ASD, ADHD and COV19 using Traditional Chinese Medicine (”TCM”) method.
Unlike some early-stage companies, where it can be difficult to parse the many ways in which founders and executives may benefit whether or not the company succeeds, RGC has taken a more transparent approach that is well-aligned with shareholders’ long-term interests.
Some highlights about the company executives and founders, showing long term conviction in the company:
- CEO to draw only $1 annual salary and no bonus until the company reaches a $1 billion market capitalization
- CEO to continue company share buyback to demonstrate commitment to the Company and position against short and distort sellers.
- All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
This brings to a healthcare stock which had been recently IPO last year July 22’ which had seen a a good run of 300% capital gains after listing. Shares have taken a heavy hit from short sellers and hedge funds whom had strategically targeting the company stock. However RGC had recovered to the $30s, encouraged by study results for Regencell’s RGC-COV19 Traditional Chinese Medicine (TCM) formula for treating COVID-19 symptoms, frequent shareholder communication, and support for the shares in the market.
[https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx](https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx)
Company CEO's Education Background and Achievements
Mr. Yat-Gai Au is the founder and CEO of Regencell. He graduated with a bachelor’s degree from UC Berkeley’s Haas School of Business and began his career in investment banking at Deutsche Bank and ING Barings.
# Education Background and Achievements RGC CEO
Some of his accomplishments in his banking career were completed over US$4 billion worth of deals and won many prestigious M&A awards. Notable deals include the US$750 million acquisition of Philippine Long Distance Telephone, the US$650 million acquisition of Indofood and the US$1.8 billion secondary placement for 40% interest in Hagemeyer, all of which were executed on behalf of First Pacific Company Limited. He is also a founding partner of one of California’s largest group of property investors and an active technology and biotech investor.
Over the years, Yat-Gai has personally seen the amazing recovery of many ADHD and ASD patients using a particular Traditional Chinese Medicine treatment.
He established Regencell in 2015, after witnessing notable improvements in many cases, including close family members who had shown ADHD and ASD symptoms. Yat-Gai is now dedicating his professional efforts and personal funds to bringing the natural formula to patients, families and caregivers around the globe.
Mr Au personnel involvement in his own philanthropic project aims to provide care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties.
As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
Yat-Gai is passionate about participating in and funding charitable activities for the elderly, gifted students and the financially underprivileged in Hong Kong and USA. During the 2020 COVID19 outbreak, he has donated over 200,000 masks to hospitals, elderlies and needy families. In September 2018, Mr. Au setup Regencell Foundation Limited to further his charitable endeavors
[https://www.topionetworks.com/people/yat-gai-au-60866c12843bac2b60498b52]
$RGC Small Cap Bioscience/Healthcare Company - ASD, ADHD and COV19 Treatments
Regencell Bioscience Holdings Limited (Nasdaq: RGC) - an early-stage bioscience company that focuses on the Research and Development and commercialization of Traditional Chinese Medicine (”TCM”) for the treatment of neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder (”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19.
In latest findings, Regencell has completed its first research study using personalized TCM formula for the treatment of ADHD and ASD in Hong Kong (where the company is located) and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
The company’s strategy will be to run the research locally in Hong Kong, and to subsequently expand its presence and treatment to other markets as part of their expansion strategy. In the company’s preparation for its future expansion, RGC has formed a JV (”joint venture”) to offer COVID-19 related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand.
The company CEO, Mr Au has shown deep conviction and believe in his company’s direction and mission. To cement his and the company’s mission, all directors and employees who were granted stock options during the company’s IPO (”Initial Public Offering”) have agreed to a lock-up for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
Moreso, Mr Au has declare that he will only receive $1 dollar annual salary and will receive no bonus until the company reaches $1 billion market capitalisation.
https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo
$RGC Small Cap Bioscience/Healthcare Company - ASD, ADHD and COV19 Treatments
Regencell Bioscience Holdings Limited (Nasdaq: RGC) - an early-stage bioscience company that focuses on the Research and Development and commercialization of Traditional Chinese Medicine (”TCM”) for the treatment of neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder (”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19.
In latest findings, Regencell has completed its first research study using personalized TCM formula for the treatment of ADHD and ASD in Hong Kong (where the company is located) and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
The company’s strategy will be to run the research locally in Hong Kong, and to subsequently expand its presence and treatment to other markets as part of their expansion strategy. In the company’s preparation for its future expansion, RGC has formed a JV (”joint venture”) to offer COVID-19 related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand.
The company CEO, Mr Au has shown deep conviction and believe in his company’s direction and mission. To cement his and the company’s mission, all directors and employees who were granted stock options during the company’s IPO (”Initial Public Offering”) have agreed to a lock-up for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
Moreso, Mr Au has declare that he will only receive $1 dollar annual salary and will receive no bonus until the company reaches $1 billion market capitalization.
https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo
Short squeeze Trade on Small Cap Healthcare Counter
Regencell Bioscience Limited’s (NASDAQ:RGC) stock that has seen a good rise of over 300% since taking the company IPO in July 2021. The company is a bioscience **healthcare** company that focuses on heavily on R&D and commercialization of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.
Analyst has covered that RGC has a undiscovered short squeeze potential. Similarities are found between RGC and GameStop Corp. $GME, where both short volume ratio are over 40% in the past year, with periods where RGC is a more heavily shorted counter than GME (~90% shorted).
As of May 16th 2022, RGC’s Founder & CEO holds 81% of total issued and outstanding ordinary shares (10,539,159). RGC’s total cumulative short volume as reported by 3rd party data analytics is over 19 million shares. Moreover, the total reported short volume to outstanding shares (excluding CEO and chairman ownership ratio) is over 7 times, which is almost 2x of GME.
[https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/]
Small Cap Drug Stocks to put in your Watchlist!
The drug/biotech sector has been witnessing developments in pipeline areas like rare diseases, gene therapy and editing, and mRNA vaccines. It is expected that innovation will continue to drive growth in the sector in 2022 with advances expected to be made in areas like Alzheimer’s, cell, gene therapy, mRNA research, treatment of neurodevelopmental disorders and Covid-19 virus.
**Assertio Holdings**
This Lake Forest, IL-based specialty pharma company, which markets neurology, inflammation and pain medications.
Earnings estimates for 2022 have improved from 35 cents per share to 40 cents per share over the past 60 days. The stock has risen 50% this year so far.
Assertio Holdings has undergone a major transformation. Its restructuring is now complete and the company has now shifted focus on growing its business. Assertio Holdings has invested in digital capabilities, resolved several legacy legal uncertainties and set up a new commercial model. The company’s successful execution of its restructuring plan has resulted in significant cost savings, which have boosted its profits despite product sales decline. The company raised its full-year adjusted EBITDA guidance in May, following strong first-quarter results and an optimistic outlook for the rest of the year.
**Regencell Bioscience Holding**
Hong Kong-based company, an early clinical stage bioscience company, founded in 2014, in the business of using traditional Chinese medicine (”TCM”) approach to develop standardized TCM formulas to holistically treat autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children, and infectious diseases which affects the immune system such as COVID-19.
For over a year (Mar 2020 - Aug 2021), RGC has established protocols and procedures for conducting Evaluation and Assessment of RGC-COV19 TCM through a Holistic approach **(EARTH)** efficacy trial in Malaysia and the United States.
The first EARTH efficacy trial (EARTH-A TRIAL) yielded promising results, with mild-to-moderate symptoms eliminated in 97.3% of the 37 patients tested (except for sensory dysfunctional or occasional cough).A trial of Earth-A was conducted with the Delta Variant.
An additional efficacy trial (EARTH-B TRIAL) was also conducted later and followed the same procedures as its predecessor, but on a larger patient scale. In this trial, 80% of the COVID-19 cases were of the Omicron variant for patients gathered in Malaysia.
**Chinook Therapeutics**
This Berkeley, CA-based biotech makes precision medicines for kidney diseases. The stock is up 12.3% this year so far.
Chinook Therapeutics’ lead clinical programmes are atrasentan and BION-1301, which are being developed for IgA nephropathy (IgAN), a serious progressive disease. Data presented from the ongoing phase I/II study of BION-1301 in patients with IgAN have demonstrated durable reductions in mechanistic biomarkers and corresponding proteinuria reductions within three months of initiating treatment. Moreover, Chinook Therapeutics believes that atrasentan, which is in phase III development for IgAN, has the potential to provide benefit in multiple chronic kidney diseases by reducing proteinuria and having direct anti-inflammatory and anti-fibrotic effects to preserve kidney function. Both candidates have been granted orphan drug designation by the European Commission for IgAN.
The stock of Viracta Therapeutics has risen 3.6% this year so far. The consensus loss estimate for 2022 has narrowed from $1.44 per share to $1.24 per share over the past 60 days.
Trending Stocks to Own Right Now!
With inflation worries high, and the Federal Reserve tightening rates aggressively, market action has been challenging so far in 2022.
Remember, there are thousands of stocks trading on the NYSE and Nasdaq. But you want to find the very best stocks right now to generate massive gains.
- Dollar General
With recession looming, even Dollar General shoppers are having to tighten their belts. U.S. consumers, the backbone of economic growth, are not as optimistic these days as they usually are.
Dollar General has struggled to top sales and earnings growth rates it posted during the pandemic. Nevertheless, the company boosted its outlook for the year in its latest quarterly report, as shoppers continue to look for deals to mitigate inflation pain
Dollar General said it expect net sales growth of 10% to 10.5% vs. previous views of about 10%. It raised its same-store sales growth forecast to around 3% to 3.5% compared with its previous expectation of 2.5%.
- Centene
Centene is benefiting from a current uptick among health stocks. It has formed a double-bottom pattern, this time with an ideal entry of 87.44.
However it has been meeting resistance at this level. It could form a handle in a few days, lowering the official entry slightly to 87.08.
The relative strength line has just hit a new high, and it remains on a strong long-term uptrend.
Earnings performance is impressive. It holds an EPS Rating of 93 out of 99. **[Earnings grew by an average of 43%](https://research.investors.com/stock-checkup/nyse-centene-corp-cnc.aspx)** over the past three quarters.
Profits are seen ramping up, with 9% growth seen this year and growth of 13% expected in 2023.
The St. Louis-based company is one of the largest Medicaid-based managed care organizations in the country. While Centene primarily provides health care products and services through Medicaid and Medicare, it also works through private insurers.
- Vertex Pharmaceuticals
In Q2, analysts expect the company to earn $3.54 per share on $2.13 billion in sales. Earnings would rise nearly 14% and sales would increase about 19%, according to FactSet.
The company is testing a replacement for pancreatic cells known as islets. Islet cells help produce insulin, but don't function properly in patients with type 1 diabetes. This leads to dangerous spikes in blood sugar. It's important to note, the program is currently on pause in the U.S. while the Food and Drug Administration reviews dosing information.
- Regencell Bioscience
Another rising healthcare bioscience along side Centene and Vertex Pharmaceuticals.
Hong Kong-based Regencell Bioscience is an early clinical stage bioscience company, founded in 2014, is in the business of using traditional Chinese medicine (”TCM”) approach to develop standardized TCM formulas to holistically treat autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children, and infectious diseases which affects the immune system such as COVID-19.
As the company is still in development stage for the TCM treatment for COV19, there isnt much findings available yet except for what the CEO has been pledging.
- Pledged to not draw salary and bonus of more than USD $1 until the Company reaches USD $1 billion market capitalization;
- Will not award share options for himself;
- All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
[https://www.investors.com/research/best-stocks-to-buy-now/?src=A00220]
(https://finance.yahoo.com/news/rgc-ceo-figuratively-putting-money-092700965.html)
Shares Buyback by CEO
Company CEO of Regencell Bioscience Holding (NASDAQ: RGC), Mr Yat-Gai Au has been buying back shares over the year (over 68.34k shares with average price of $USD 26). The company stock price dropped in last month’s lowest of $USD 28.60 becoming its new support line.
Analyst data recorded that Mr Au’s recent purchase of shares was the biggest made as an insider individual.
That means that an insider was happy to buy shares at above the current price. It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares.
As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. Yat-Gai Au was the only individual insider to buy shares in the last twelve months.
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests.
Regencell Bioscience Holdings insiders own 81% of the company, currently worth about US$260m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
[https://finance.yahoo.com/news/founder-regencell-bioscience-holdings-limited-101443485.html]
Invest in Defensive Counter Now! Diversifying Portfolio
The Fed is raising interest rates aggressively in an attempt to tame raging inflation and this has been hurting many stock investors who’s seeing bleeding portfolios on their phone or desktops.
Companies are predicted to slash forecasted earnings in the coming earnings quarter due to the high inflation rates and possible slowdown in earnings.
Unlike some early-stage companies, where it can be difficult to parse the many ways in which founders and executives may benefit whether or not the company succeeds, RGC has taken a more transparent approach that is well-aligned with shareholders’ long-term interests.
Some highlights about the company executives and founders, showing long term conviction in the company:
- CEO to draw only $1 annual salary and no bonus until the company reaches a $1 billion market capitalization
- CEO to continue company share buyback to demonstrate commitment to the Company and position against short and distort sellers.
- All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
[https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx](https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx)
Regencell Bioscience : Announces First Half 2022 Management Financial Results - Form 6-K
Regencell Bioscience Limited (Nasdaq: RGC), announced its unaudited interim financial results for the six months ended December 31, 2021.
Some of the important notes are highlighted below,
Recent Developments
Entry into Joint Venture Agreement on September 2, 2021, Regencell Bioscience Limited entered into a joint venture agreement (the "JV Agreement") with Honor Epic Enterprises Limited ("Honor Epic"), a company incorporated in the British Virgin Islands, to form a joint venture under the laws of Hong Kong.
Operation Expenses
During the six-month period ended December 31, 2021, we incurred total operating expenses of approximately $3.7 million, an increase of approximately $3.3 million, or 893%, as compared to total operating expenses of approximately $0.4 million during the six-month period ended December 31, 2020
General and administrative expenses increased by approximately $2.4 million, or 2,106%, to approximately $2.5 million for the six-month period ended December 31, 2021 from approximately $0.1 million for the six-month period ended December 31, 2020. The increase was mainly attributable to
(i) approximately $1.0 million in amortization of share based payments for our general and administrative personnel for the six-month period ended December 31, 2021,
(ii) approximately $0.5 million increase in professional fees, such as legal services and public relations services as we became a public company listed on the Nasdaq Capital Market,
(iii) approximately $0.4 million increase in salaries due to the increase in the number of staff and bonus payments during the six-month period ended December 31, 2021,
(iv) approximately 0.3 million increase in rental expenses due to the rental of new office and staff quarters,
(v) approximately 0.2 million increase in traveling and entertainment and others mainly due to more business activities since our operation expanded during the six-month period ended December 31, 2021
Other Income, Net
Total other income, net was approximately $100 for the six-month period ended December 31, 2021 and total other income, net was approximately $35,000 for the six-month period ended December 31, 2020.
Other income mainly consisted of cash received from a government grant and interest income. Other income decreased to approximately $100 for the six-month period ended December 31, 2021 from approximately $35,000 for the six-month period ended December 31, 2020, because the Company did not receive any government grants in respect of COVID-19-related subsidies from the Employment Support Scheme provided by the Hong Kong Government under the Anti-Epidemic Fund during the six-month period ended December 31, 2021
Cash
As of December 31, 2021, we had cash of approximately $19 million compared to approximately $0.06 million as of June 30, 2021. The increase of cash was mainly due to the receipt of net IPO proceeds from the completion of our IPO in July 2021. The net proceeds of the IPO, including proceeds from the sale of Over-allotment Shares, totaled approximately $22.7 million, after deducting underwriting discounts and other related expenses of approximately $2.3 million.
[https://m.marketscreener.com/quote/stock/REGENCELL-BIOSCIENCE-HOLD-124803353/news/Regencell-Bioscience-Announces-First-Half-2022-Management-Financial-Results-Form-6-K-40625825/]
Small Cap - Healthcare Stock - RGC - Moonshot Potential!!
Regencell Bioscience Holdings Limited (Nasdaq: RGC) is an early-stage bioscience company that focuses on the R&D and commercialization of Traditional Chinese Medicine (”TCM”) for the treatment of neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder (”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19.
In latest findings, Regencell Bioscience’s (TCM) has treatment formula has so far treated 12 / 19 patients (suspected or confirmed COVID cases), and their health records showed improvements after an average treatment period of 5 days.
The company’s CEO and chairman noted “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."
The company’s current plan is to trade, manufacture, market and distrubte the TCM formulae for the treatment of COVID-19 to ASEAN countries, India, Japan, Australia and New Zealand.
Aside from the Company’s mission to threat people with ADHD and ASD, the company CEO, Mr Au is also involved in his own philanthropic project (within personal capacity) and aims to provided care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties. As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
[https://www.biospectrumasia.com/news/48/18957/regencell-bio-to-offer-traditional-medicines-for-covid-19-treatment-in-asean-countries.html]
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
Insiders Percentage and they have not stop buying / $RGC
In investing, it is always worth while to find out who are the majority shareholders of the company. Understanding of business ownership structure is vital as it determines who is in control of the company and its direction. Moreso, having a large number of shares would either benefit or loses most when the stock price moves.
Data shows that insiders recently bought shares in the company and they were rewarded after market cap rose US$64m last week.
Small companies that are not very actively traded often, thus lack institutional investors. It is more common to see institutional investors in larger companies instead.
There are multiple explanations for why institutions don't own a stock. The most common is that the company is too small relative to funds under management, so the institution does not bother to look closely at the company. Alternatively, there might be something about the company that has kept institutional investors away.
Hedge funds don't have many shares in Regencell Bioscience Holdings. With a 81% stake, CEO Yat-Gai Au is the largest shareholder. It's usually considered a good sign when insiders own a significant number of shares in the company, and in this case, it’s glad to see a company insider with such skin in the game. In comparison, the second and third largest shareholders hold about 7.6% and 0.1% of the stock.
With a 11% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Regencell Bioscience Holdings. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
With a stake of 7.6%, private equity firms could influence the Regencell Bioscience Holdings board. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.
[https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgc/regencell-bioscience-holdings/news/regencell-bioscience-holdings-limited-nasdaqrgc-insiders-hav]
Investors should turn to Healthcare Defensive Stocks to Weather This Current Sentiment
U.S. stocks extended losses at Tuesday's open as investors mulled disappointing earnings from Walmart and General Motors and braced for results from Big Tech due out after the bell.
The benchmark S&P 500 tumbled 0.6%, while the Dow Jones Industrial Average declined by roughly 100 points, or 0.3%. The technology-heavy Nasdaq Composite fell 1.1%.
Volatile periods calls for a reshuffling of portfolio in many investors and traders where they may opt for defensive sector equities ie. REITs, F&B, Utilities or Healthcare which has shown resilience against market turbulent.
Regencell bioscience, a healthcare company stock was also affected by the market, seeing drops of around 30% from last week’s peak. Investors who are looking to own this stock could find the current price attractive and begin collecting the ticker.
Regencell is a recently IPO in July 2021, and had seen a staggering rise of >300% in share price weeks after being listed.
Regencel Bioscience Holding is a R&D and Commercialize Healthcare company that focusses on treating ADHD, ASD and COVID-19 using Traditional Chinese Medicine (”TCM”) approach.
In the past, the company had been through rainy and rough days of being shorted by both short sellers and traders alike which had been strategically planned. Some journalists even compared the short attacked to be identical or even more severe than what happened to the infamous GameStop (GME)
The Company CEO, a practicing TCM practitioner (Mr Au) did not taken this event without a stand. Mr Au has voiced out “Short and distort schemes used on our stock are negatively affecting our company. These schemes hurt our investors and patients, especially children and their families who are looking for a natural approach to treat attention hyperactivity disorder (“ADHD”), autism spectrum disorder (“ASD”) and COVID-19, and have the potential to disrupt our mission to help our patients.”
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
Mr Au took further response by buying back over 5 million ordinary shares to defend the company against these short sellers and has also announced that he will not be drawing salary nor bonus (<1$) until the company reaches $1 Billion USD.
Further stance were taken by the company’s directors and employees where stock options which were previously granted upon company IPO will be subjected to a lock-up of 6 months vesting period. The shares will be locked up until January 16, 2023.
Small Cap Medical Stock, treating ASD, ADHD and COV19
Regencell Bioscience Holdings Limited (Nasdaq: RGC) - an early-stage bioscience company that focuses on the Research and Development and commercialization of Traditional Chinese Medicine (”TCM”) for the treatment of neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder **(”**ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19.
In latest findings, Regencell has completed its first research study using personalized TCM formula for the treatment of ADHD and ASD in Hong Kong (where the company is located) and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
The company’s strategy will be to run the research locally in Hong Kong, and to subsequently expand its presence and treatment to other markets as part of their expansion strategy. In the company’s preparation for its future expansion, RGC has formed a JV (”joint venture”) to offer COVID-19 related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand.
The company CEO, Mr Au has shown deep conviction and believe in his company’s direction and mission. To cement his and the company’s mission, all directors and employees who were granted stock options during the company’s IPO (”Initial Public Offering”) have agreed to a lock-up for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
Moreso, Mr Au has declare that he will only receive $1 dollar annual salary and will receive no bonus until the company reaches $1 billion market capitalization.
Choose Defensive Stock for Volatile Market
# Defensive Stance in Downtrend Market : Regencell ($RGC)
The past months of market volatility has not been kind to many tech and growth sector stocks which has seen large drops between 30-50%. The recent beatdown of these sectors are mainly due to the market uncertainty of growing inflation numbers, quantitative easing of Fed's reserve, Russian-Ukraine War and rise in oil pricing.
The market has diverted its attention from the growth sector and into defensive sectors ie. healthcare, utilities and consumer staple; which are less volatile and less sensitive to the economic cycle. The simple understanding is that these sectors fall under human essential services, necessary for any day to day affair.
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialization of Traditional Chinese Medicine (TCM) treatment specifically ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), and infectious diseases affecting people’s immune system such as COVID.
The company's CEO (Mr. Yat-Gai Au), since IPO day has bought over $5 million of ordinary shares and has not sold any shares despite the having seen the stock price rose staggeringly. The company is currently in the business for the long run and will continue to be vested in its business model of developing treatments for AHDH and ASD as treatment trials are ongoing.
[https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/]
$RGC Defensive Stock to include in your Portfolio (HEALTHCARE)
Investors and traders alike has seen stock market and crypto market tanked in the past several months due to multiple black swan events ie. Russian-Ukraine War, Fall of Luna/Terra, US Rate hikes, Surge in oil price, and amongst other things, INFLATION.
During this bear market, majority of stock companies and crypto prices have tank-ed, but there is a company that is currently showing resilience and is on an uptrend.
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialization of Traditional Chinese Medicine (TCM) treatment specifically ADHD and ASD, and infectious diseases targeting people’s immune system ie. COVID.
The stock price has seen 300% growth since IPO. The stock price has seen days of being shorted by traders in recent months. We will be monitoring these next few days if the stock price will rally to its previous ATH again.
The company's CEO (Mr. Yat-Gai Au), since IPO day has bought over $5 million of ordinary shares and has not sold any shares despite the having seen the stock price rose staggeringly. The company is currently in the business for the long run and will continue to be vested in its business model of developing treatments for AHDH and ASD as treatment trials are ongoing.
[https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/]
A Strong Management Company for Your Watchlist $RGC
A company with strong financials is crucial. However, a company with strong leadership and management is equally as critical to the long term growth of a company.
When investors look for a company, the quantitative aspect is usually sought-after (ie. profit growth, cash flow, debt, etc) as the primary focus. However the qualitative (company leadership and management), nature of the company should also be taken into consideration. Qualitative assets are usually harder to detect as they are not quantifiable but numbers and figures.
Examples of successful companies with strong qualitative are like META (previously Facebook).
Meta grew as it holds appeal to the public and has been smart about acquiring businesses and recruiting/retaining talents. The CEO’s efforts (Mark Zuckerberg) also grin up near-term revenue prospects with its push into TV-like contents.
Presently, we take a look at a defensive healthcare company (RGC) Regencell Bioscience Ltd. A company focusing on using Traditional Chinese Medicine to treat ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), and infectious diseases affecting people’s immune system such as COVID.
Since listing, the company CEO has purchased over $5 MIL of ordinary shares and has yet to sold any as of today. This qualitative aspect of the company displays the company and managements confidence and conviction about the company’s direction and future.
Moreso, the CEO will continue to deployed personnel funds buying back shares all against the market shorters and sellers.
The company has a prominent investment backer, Samuel Chen, who had a significant position in ZOOM (8.8% holding) post-IPO and Zoom’s market capitalization peaked at US$161 billion on 19 October 2020.
Investors should always remember to look into the qualitative face of the company, as it does play a part in identifying the strength of the company.
[https://money.usnews.com/investing/articles/2017-06-12/10-of-the-best-managed-public-companies]
$RGC Healthcare Stock for your watchlist - Using Traditional Chinese Medicine (TCM) Method
Regencell Bioscience Holdings Limited (Nasdaq: RGC) a bioscience company focusing on treatment using Traditional Chinese Medicine (”TCM”) on neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder (”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19. The company is mainly focusing on both R&D of these treatments and also commercialization of the medicine once conclusive results are met.
In latest findings, Regencell Bioscience’s (TCM) has treatment formula has so far treated 12 / 19 patients (suspected or confirmed COVID cases), and their health records showed improvements after an average treatment period of 5 days.
The company’s CEO and chairman noted “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."
The company’s current plan is to trade, manufacture, market and distrubte the TCM formulae for the treatment of COVID-19 to ASEAN countries, India, Japan, Australia and New Zealand.
Aside from the Company’s mission to threat people with ADHD and ASD, the company CEO, Mr Au is also involved in his own philanthropic project (within personal capacity) and aims to provided care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties. As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
[https://www.biospectrumasia.com/news/48/18957/regencell-bio-to-offer-traditional-medicines-for-covid-19-treatment-in-asean-countries.html]
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
$RGC Potential Bagger healthcare Company - HOT STOCK -
Regencel Bioscience Holding is a R&D and Commercialize Healthcare company that focusses on treating ADHD, ASD and COVID-19 using Traditional Chinese Medicine (”TCM”) approach.
The company’s stock has seen rough days of being shorted by both short sellers and traders alike and the Company CEO has not taken this event without a stand. Mr Au, the CEO of Regencell has voiced out “Short and distort schemes used on our stock are negatively affecting our company. These schemes hurt our investors and patients, especially children and their families who are looking for a natural approach to treat attention hyperactivity disorder (“ADHD”), autism spectrum disorder (“ASD”) and COVID-19, and have the potential to disrupt our mission to help our patients.”
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
Mr Au took further response by buying back over 5 million ordinary shares to defend the company against these short sellers and has also announced that he will not be drawing salary nor bonus (<1$) until the company reaches $1 Billion USD.
Further stance were taken by the company’s directors and employees where stock options which were previously granted upon company IPO will be subjected to a lock-up of 6 months vesting period. The shares will be locked up until January 16, 2023.
$RGC Online Interview sharing outcome of TCM's Treatment
Regencell Bioscience Limited is a Hong Kong company which is fronting the uses of Traditional Chinese Medicine (”TCM”) to treat not only ADHD and ASD but also Covid-19 which shook the world back in 2020.
Regencell is currently a listed Company in NASDAQ market in the US with its ticker $RGC.
At present, RGC has treatment formula has test treated 19 patients (suspected or confirmed COVID cases). 12 of 19 patients which were treated exhibited improvements in their recovery after an average treatment period of 5 days.
An interview was held on SSN Network (The Official Small-, Micro- and Nano-Cap News Source™) which included Jay Lee, CEO of Regencell Bioscience Asia Limited, and Paul Niewiadomski, Independent Director; where they talk about the company, the procedures and protocols of their treatments and result findings.
[https://finance.yahoo.com/news/regencell-describes-traditional-chinese-medicine-133000084.html]
Separately, while Mr Au, the company’s CEO and chairman was not included as part of the interview, he has been working in in the background in defending his company from the recent short seller and trader attacks on the company stock. Mr Au has bought back over $5 Million Dollars of company share since taking the company IPO.
Mr Au has mentioned “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."
Aside from the company’s positive progress in medical, the CEO (Mr Au) has shown his confidence in the progress of the company direction and not sold a single share since taking his company to Initial Public Offering (”IPO”) in Year 2020. Mr Au has pledged to not take salary and bonus (<1$) until the company reaches US$1 Billion market cap as his target.
[https://www.biospectrumasia.com/news/48/18957/regencell-bio-to-offer-traditional-medicines-for-covid-19-treatment-in-asean-countries.html]
Company CEO Stepping Up in Shutting down Short Sellers and Hedge Funds
CEO of Regencell Bioscience Holdings has voiced out against traders who are shorting and putting out negative schemes on the company stock, negatively impacting the company’s image.
Regencell Bioscience Holdings (RGC: Nasdaq) is a an early-staged bioscience healthcare company focusing on R&D and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.
These negative schemes have indirectly put harm to RGC investors and patients whom rely on the company’s developments to develop a natural approach towards treatment of Attention Hyperactive Disorder (ADHD) Autism Spectrum Disorder (ASD) and Covid-19.
RGC’s CEO (Mr Yat-Gai Au) has agreed to continue draw 1$ annual salary and with no bonuses until the company has reached $1 Billion market cap and reserve share options for all employees except himself. He has even pledged to continue putting personal funds to buyback company shares to display his commitment to the company and his stances against short sellers.
More so, to further demonstrate the company’s commitment, all directors and employees who were granted with stock options during IPO have agreed to a 6 months lockup after it is vested. These stocks options will be vested on July 16th 2022, hence it will remain locked until Janurary 16th 2023.
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
$RGC - A company with Strong leadership that puts money where his mouth is!
A company with strong financials is crucial. However, a company with strong leadership and management is equally as critical to the long term growth of a company.
When investors look for a company, the quantitative aspect is usually sought-after (ie. profit growth, cash flow, debt, etc) as the primary focus. However the qualitative (company leadership and management) nature of the company should also be taken into consideration. Qualitative assets are usually harder to detect as they are not quantifiable but numbers and figures.
Examples of successful companies with strong qualitative are like META (previously Facebook).
Meta grew as it holds appeal to the public and has been smart about acquiring businesses and recruiting/retaining talents. The CEO’s efforts (Mark Zuckerberg) also grin up near-term revenue prospects with its push into TV-like contents.
Presently, we take a look at a defensive healthcare company (RGC) Regencell Bioscience Ltd. A company focusing on using Traditional Chinese Medicine to treat ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), and infectious diseases affecting people’s immune system such as COVID.
Since listing, the company CEO has purchased over $5 MIL of ordinary shares and has yet to sold any as of today. This qualitative aspect of the company displays the company and managements confidence and conviction about the company’s direction and future.
Moreso, the CEO will continue to deployed personnel funds buying back shares all against the market shorters and sellers.
The company has a prominent investment backer, Samuel Chen, who had a significant position in ZOOM (8.8% holding) post-IPO and Zoom’s market capitalization peaked at US$161 billion on 19 October 2020.
Investors should always remember to look into the qualitative face of the company, as it does play a part in identifying the strength of the company.
https://money.usnews.com/investing/articles/2017-06-12/10-of-the-best-managed-public-companies
$RGC - A company with Strong leadership that puts money where his mouth is!
A company with strong financials is crucial. However, a company with strong leadership and management is equally as critical to the long term growth of a company.
When investors look for a company, the quantitative aspect is usually sought-after (ie. profit growth, cash flow, debt, etc) as the primary focus. However the qualitative (company leadership and management) nature of the company should also be taken into consideration. Qualitative assets are usually harder to detect as they are not quantifiable but numbers and figures.
Examples of successful companies with strong qualitative are like META (previously Facebook).
Meta grew as it holds appeal to the public and has been smart about acquiring businesses and recruiting/retaining talents. The CEO’s efforts (Mark Zuckerberg) also grin up near-term revenue prospects with its push into TV-like contents.
Presently, we take a look at a defensive healthcare company (RGC) Regencell Bioscience Ltd. A company focusing on using Traditional Chinese Medicine to treat ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), and infectious diseases affecting people’s immune system such as COVID.
Since listing, the company CEO has purchased over $5 MIL of ordinary shares and has yet to sold any as of today. This qualitative aspect of the company displays the company and managements confidence and conviction about the company’s direction and future.
Moreso, the CEO will continue to deployed personnel funds buying back shares all against the market shorters and sellers.
The company has a prominent investment backer, Samuel Chen, who had a significant position in ZOOM (8.8% holding) post-IPO and Zoom’s market capitalization peaked at US$161 billion on 19 October 2020.
Investors should always remember to look into the qualitative face of the company, as it does play a part in identifying the strength of the company.
https://money.usnews.com/investing/articles/2017-06-12/10-of-the-best-managed-public-companies
HIDDEN GEM STOCK - $RGC Regencell Bioscience Business and its CEO
Regencell Bioscience Holdings Limited (Nasdaq: RGC) is an early-stage bioscience company that focuses on the R&D and commercialization of Traditional Chinese Medicine (”TCM”) for the treatment of neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder (”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19.
In latest findings, Regencell has completed its first research study using personalized TCM formula for the treatment of ADHD and ASD in Hong Kong (where the company is located) and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
The company’s strategy will be to run the research locally in Hong Kong, and to subsequently expand its presence to other markets as part of their expansion strategy. In the company’s preparation for its future expansion, RGC has formed a JV (”joint venture”) to offer COVID-19 related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand.
The company CEO, Mr Au has shown deep conviction and believe in his company’s direction and mission. To cement his and the company’s mission, all directors and employees who were granted stock options during the company’s IPO (”Initial Public Offering”) have agreed to a lock-up for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
Moreso, Mr Au has declare that he will only receive $1 dollar annual salary and will receive no bonus until the company reaches $1 billion market capitalization.
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
JUICY SHORT SQUEEZE PLAY HERE BOYS $GME $RGC
Fellow Redditors of r/wallstreetbets took Wall Street by storm when they rally against hedge funds and showing the high and mighty folks in fancy suits who’s the boss by short squeezing $GME (GameStop) stock. The stock of GME reached a premarket value of over $500 per share. The price was nearly 30 times the $17.25 valuation at the beginning of January 2021; putting big losses to hedge funds and also sending some of them packing (filed for bankrupcy).
A similar potential is seen in $RGC Regencell Bioscience Holdings where the short volume ratio has a similar pattern to that of GameStop with both averaging over 40% in the past year.
Moreso, Regencell found to be shorted occasional days close to 90%, higher than GameStop.
Regencell’s total cumulative short volume, as reported by a third-party data analytics provider, is over 19 million shares, while the total outstanding shares less CEO and Chairman’s shares is only approximately 2.4 million, yet Regencell is still trading over 289% its IPO price.
Its total reported short volume to outstanding shares ratio (excluding CEO and Chairman’s shares ratio) is almost double of GameStop, being approximately 8 times whereas GameStop is slightly over 4 times. GameStop is currently trading 50x over its historical low of $2.52.
Little is known if there will be any short squeeze happening on RGC but it is something aggresive or awared traders could keep in their watchlist.
[https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i]
$RGC HUGE Shortsqueeze potential on Healthcare Counter
Regencell Bioscience Limited’s (NASDAQ:RGC) stock that has seen a good rise of over 300% since taking the company IPO in July 2021. The company is a bioscience **healthcare** company that focuses on heavily on R&D and commercialisation of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.
Analyst has covered that RGC has a undiscovered short squeeze potential. Similarities are found between RGC and GameStop Corp. $GME, where both short volume ratio are over 40% in the past year, with periods where RGC is a more heavily shorted counter than GME (~90% shorted).
As of May 16th 2022, RGC’s Founder & CEO holds 81% of total issued and outstanding ordinary shares (10,539,159). RGC’s total cumulative short volume as reported by 3rd party data analytics is over 19 million shares. Moreover, the total reported short volume to outstanding shares (excluding CEO and chairman ownership ratio) is over 7 times, which is almost 2x of GME.
[https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/]
For Short volume available, to look up at https://fintel.io/ss/us/rgc#
$RGC, a long lost twin of GME? - Shortsqueeze potential!!
Regencell Bioscience Limited’s (TICKER: RGC) stock is an undiscovered short squeeze potential. The short volume ratio has similar pattern as that of GameStop Corp. (TICKER: GME), whereby both averaged over 40% in the past year. In fact, RGC is more heavily shorted than GME as some days were close to 90% shorted.
However, as much as RGC and GME stock’s short volume profile is similar, not much is known about the facts and figures of RGC, which is provided below. As of 16 May 2022, RGC’s founder and CEO holds 10,539,159 ordinary shares, representing 81.0% of the total number of issued and outstanding ordinary shares in RGC. RGC’s total cumulative short volume as reported by third party data analytics provider is over 19 million shares and RGC’s total reported short volume to outstanding shares (excluding CEO and Chairman ownership ratio) is over 7 times, which is almost double that of GME. Where are all the extra shares coming from?
A short squeeze on GME created a return of 51x (current price to its historical low) to 191x (historical high to its historical low), what is the potential for RGC if there is a short squeeze?
https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/
RGC Founder; Yat-Gai Au, Just Bought A Few More Shares
Those following along with Regencell Bioscience Holdings Limited will no doubt be intrigued by the recent purchase of shares by Yat-Gai Au, Founder of the company, who spent a stonking US$1.2m on stock at an average price of US$25.23. While that only increased their holding size by 0.5%, it is still a big swing by our standards.
Regencell Bioscience Holdings Insider Transactions Over The Last Year
In fact, the recent purchase by Yat-Gai Au was the biggest purchase of Regencell Bioscience Holdings shares made by an insider individual in the last twelve months, according to our records. That means that an insider was happy to buy shares at above the current price of US$24.86. It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares. As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. Yat-Gai Au was the only individual insider to buy shares in the last twelve months.
Yat-Gai Au purchased 68.34k shares over the year. The average price per share was US$26.03. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below.
https://finance.yahoo.com/news/founder-regencell-bioscience-holdings-limited-101443485.html